ORMP - Oramed Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
8/30/2018
8/30/2017
8/30/2016
Total Revenue
2,639
2,449
2,456
641
Cost of Revenue
90
86
187
490
Gross Profit
2,549
2,535
2,269
151
Operating Expenses
Research Development
14,056
11,979
10,281
7,709
Selling General and Administrative
3,929
4,083
2,759
2,452
Total Operating Expenses
17,985
16,062
13,040
10,161
Operating Income or Loss
-15,436
-13,527
-10,771
-10,010
Interest Expense
-
-
-
93
Total Other Income/Expenses Net
-
-30
-10
-17
Income Before Tax
-14,701
-12,727
-10,080
-9,629
Income Tax Expense
300
0
400
1,335
Income from Continuing Operations
-15,001
-12,727
-10,480
-10,964
Net Income
-15,001
-12,727
-10,480
-10,964
Net Income available to common shareholders
-15,001
-12,727
-10,480
-10,964
Reported EPS
Basic
-
-0.86
-0.79
-0.87
Diluted
-
-0.86
-0.79
-0.87
Weighted average shares outstanding
Basic
-
14,882
13,309
12,624
Diluted
-
14,882
13,309
12,624
EBITDA
-
-13,521
-10,766
-10,006